TIBET PHARMA(SH:600211) Zheng Xing Xing Ye Ri Bao·2025-09-15 08:42Market Overview - The biopharmaceutical sector experienced a decline of 0.7% on September 15, with Tibet Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3860.5, down 0.26%, while the Shenzhen Component Index closed at 13005.77, up 0.63% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Wu Fan Bio: Closed at 59.20, up 9.10% with a trading volume of 71,800 shares and a turnover of 418 million [1] - Kangchen Pharmaceutical: Closed at 57.81, up 5.24% with a trading volume of 64,400 shares and a turnover of 374 million [1] - ST Weiming: Closed at 8.39, up 5.01% with a trading volume of 77,500 shares and a turnover of 6.38 million [1] - Conversely, significant decliners included: - Tibet Pharmaceutical: Closed at 54.11, down 4.11% with a trading volume of 139,000 shares and a turnover of 773 million [2] - Junshi Biosciences: Closed at 47.43, down 2.81% with a trading volume of 176,300 shares and a turnover of 847 million [2] - Wo Wu Bio: Closed at 30.47, down 2.59% with a trading volume of 114,600 shares and a turnover of 3.55 billion [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 450 million from institutional investors, while retail investors contributed a net inflow of 190 million [2] - The capital flow for specific stocks indicated: - Changchun High-tech: Net inflow of 59.31 million from institutional investors, but a net outflow of 89.17 million from retail investors [3] - Kanghua Bio: Net inflow of 47.58 million from institutional investors, with outflows from retail investors totaling 28.74 million [3] - Kexing Pharmaceutical: Net inflow of 38.60 million from institutional investors, but a net outflow of 25.43 million from retail investors [3]